Oxis International Inc., of Los Angeles, and Altor Bioscience Corp., of Miramar, Fla., agreed to collaborate exclusively in the development of a 161533 trispecific killer engager (Trike) fusion protein for cancer therapies. The Trike technology, developed by researchers at the University of Minnesota Masonic Cancer Center, was shown in nonclinical models to direct immune cells to kill cancer cells while diminishing drug-related toxicity.